Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Report and Forecast 2024-2032

Global Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Outlook

The chronic inflammatory demyelinating polyneuropathy treatment market attained a value of USD 4.13 billion in 2023. The market is expected to rise at a CAGR of 6.9% in the forecast period of 2024-2032 and is anticipated to be worth USD 7.52 billion by 2032.

Chronic Inflammatory Demyelinating Polyneuropathy: Disease Insights

Chronic inflammatory demyelinating polyneuropathy is a rare neuroinflammatory disorder. The destruction of nerve fibre myelin sheaths and inflammation of nerve roots takes place in this disorder. The reduction of myelin causes nerve signals blockage and thus, substantial loss in the nerve fibres.

The severity of the disease, duration of disease and symptoms vary from patient to patient. The common signs and symptoms of chronic inflammatory demyelinating polyneuropathy are impaired body movements, weakness of both muscles and paralysis in extreme cases. The disfigurement in the motor and sensory functions affects both sides of the body.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

There are different variants of chronic inflammatory demyelinating polyneuropathy such as multifocal variants, pure sensory variants, distal variants, and pure motor variants. The exact cause of CIDP is still not clear, but the studies suggest, it to be an autoimmune disorder.

The diagnosis of chronic inflammatory demyelinating polyneuropathy is a bit complicated, due to the very common symptoms. Electromyography is the primary test used to analyse the velocities of nerve conduction. Lumbar puncture and MRI imaging are the additional diagnostic tests of CIDP. These tests help in the detection of enlargement and indications of pain.

Several approved treatments are used for the management of chronic inflammatory demyelinating polyneuropathy.

According to the chronic inflammatory demyelinating polyneuropathy treatment market research report, the market can be categorised into the following segments:

Market Breakup by Therapeutic Method

• Corticosteroids

• Intravenous Immunoglobulin

• Plasma exchange

• Immunotherapy

• Stem Cell Transplant

• Physical therapy

• Others

Market Breakup by Diagnosis

• Electrodiagnostic Testing

• Nerve Conduction

• Electromyography

• Spinal Fluid Analysis

• Others

Market Breakup by Route of Administration

• Intravenous

• Oral

• Others

Market Breakup by End User

• Hospitals

• Specialty Neurological Clinics

• Research and Academic Laboratories

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The increasing incidence and prevalence of CIDP are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market. According to National Organisation for Rare Disorders, every 5-7 individuals per 100,000 are diagnosed with CIDP. The rising cases of CIDP are propelling the demand for the treatment market.

The growing research and development activities will lead to the discovery of novel targeted therapies. At present, according to clinicaltrials.gov, more than thirty-eight clinical trials are under current evaluation.

The CIDP organisations and international support groups are creating awareness regarding the diagnosis and treatment of CIDP. Raising awareness and support initiatives have stimulated the growth of the market.

With technological advancements, there are innovations in diagnostic tools and interventions. This will assist in more specific and accurate detection. The advancements in diagnostic techniques are also aiding the growth of the market.

North America Accounts for the Largest Share

North America is anticipated to hold the maximum share in the CIDP market. Increased expenditure in the healthcare sector and greater research and developmental activities are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market.

Therapeutic Landscape

There are multiple therapeutic strategies approved for the management of chronic inflammatory demyelinating treatment. The available treatments suppress the immune system and thus, there are high chances of infections and other related disorders.

Standard Therapies: Corticosteroids, Immunoglobins, Plasma Exchange and Immunosuppressants are Aiding the Growth of the Market

Glucocorticosteroids are the first-line medications for treating CIDP. These drugs are used in combination with other immunosuppressive drugs to provide more efficient treatment. Prednisone is one of the most common drugs belonging to this category.

Intravenous immunoglobin has also shown promising effects in the treatment of CIDP. This therapy increases immunity and assists in the treatment. Subcutaneous immunoglobin delivery is an alternative form of IVIG therapy.

Plasma Exchange is the chronic treatment for the management of chronic inflammatory demyelinating polyneuropathy. In this therapeutic procedure, immunoglobins and other components are extracted from the immunity system. The plasma and its constituents are also removed from the affected individual and then replaced with albumin. The blood cells are transfused back into the patient. 

Immunosuppressive agents are also used for treating chronic inflammatory demyelinating polyneuropathy. Some examples of such agents are mycophenolate, cyclosporine, and azathioprine. The discovery of novel immunosuppressants is anticipated to fuel the chronic inflammatory demyelinating polyneuropathy treatment market growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Clinical Trial Landscape

With the increase in disease prevalence, there is a need for novel therapeutic interventions. These new treatments are anticipated to provide lucrative opportunities in the therapeutic sector.

Emerging Therapies: Monoclonal Antibodies, FcRN Inhibitors, and HYQVIA Therapy

The clinical trials for the incorporation of monoclonal antibodies in the standard treatments are under evaluation. Monoclonal antibodies are artificially made proteins resembling the immune system’s pathogenic defence mechanism.

Rituximab, a monoclonal antibody has recently been approved by the USFDA for the treatment of multiple sclerosis and rheumatoid arthritis.

The investigation for reducing circulating immunoglobins is also under process. These studies incorporate the activity of FcRN inhibitors that will assist in the management of chronic inflammatory demyelinating polyneuropathy.

Takeda, a key player is performing the final stage of clinical trials for a recombinant therapy HYQVIA. This therapy incorporates human hyaluronidase with a ten per cent infusion of human immunoglobins. The company aims to get approvals from the USFDA and EMA by the end of 2023. If approved, this can be used as maintenance therapy for alleviating the symptoms of chronic inflammatory demyelinating polyneuropathy.

Implementing advanced technologies in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for recombinant therapies. Several ongoing clinical trials are emerging as a driving factor for the market growth and development.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the chronic inflammatory demyelinating polyneuropathy treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Grifols, S.A.

• Octapharma AG

• Baxter International Inc.

• Pfizer Inc.

• CSL Behring LLC

• MedDay SA

• Shire plc

• Takeda Pharmaceutical Company Limited

• Teijin Limited

• Momenta Pharmaceuticals, Inc.

Key Highlights of the Report